{"symbol":"LLY","fiscalQuarter":"Q1-2025","reportDate":"2025-05-01","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q1-2025","postBrief":{"headline":"Eli Lilly Misses on EPS, Stock Down 11.66%","keyNumbers":[{"metric":"EPS","actual":"$3.34","expected":"N/A","surprise":"-5.01%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged challenges in meeting earnings expectations.","They emphasized ongoing investments in research and development."],"summary":"Overall, management expressed concern over recent performance but highlighted their commitment to innovation. They did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Eli Lilly's earnings report indicates a slight miss on EPS, which contributed to a significant drop in stock price by 11.66%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are aware of the challenges ahead but remain focused on long-term growth through R&D investments.","metaDescription":"Eli Lilly (LLY) Q1 2025 earnings: EPS missed expectations. Stock down 11.66%. Full breakdown."}}